Immunometabolic Regulation of Interleukin-17-Producing T Helper Cells: Uncoupling New Targets for Autoimmunity by Katrina J. Binger et al.
March 2017 | Volume 8 | Article 3111
Mini Review
published: 21 March 2017
doi: 10.3389/fimmu.2017.00311
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Ping-Chih Ho, 
University of Lausanne, Switzerland
Reviewed by: 
Laura Solt, 
Scripps Research Institute, USA 
Chia-Lin Hsu, 
National Yang-Ming University, 
Taiwan  
Guoliang Cui, 
Deutsches Krebsforschungszentrum 
(DKFZ), Germany
*Correspondence:
Markus Kleinewietfeld  
markus.kleinewietfeld@vib- 
uhasselt.be
Specialty section: 
This article was submitted to 
Molecular Innate Immunity, 
a section of the journal 
Frontiers in Immunology
Received: 06 January 2017
Accepted: 06 March 2017
Published: 21 March 2017
Citation: 
Binger KJ, Côrte-Real BF and 
Kleinewietfeld M (2017) 
Immunometabolic Regulation of 
Interleukin-17-Producing T Helper 
Cells: Uncoupling New Targets for 
Autoimmunity. 
Front. Immunol. 8:311. 
doi: 10.3389/fimmu.2017.00311
immunometabolic Regulation of 
interleukin-17-Producing T Helper 
Cells: Uncoupling new Targets for 
Autoimmunity
Katrina J. Binger1, Beatriz F. Côrte-Real2 and Markus Kleinewietfeld2*
1 Department of Biochemistry and Molecular Biology, Bio21 Institute of Molecular Science and Biotechnology, University of 
Melbourne, Parkville, VIC, Australia, 2 VIB Laboratory of Translational Immunomodulation, Hasselt University, BIOMED, 
Diepenbeek, Belgium
Interleukin-17-producing T helper (Th17) cells are critical for the host defense of bacterial 
and fungal pathogens and also play a major role in driving pathogenic autoimmune 
responses. Recent studies have indicated that the generation of Th17 cells from naïve 
CD4+ T cells is coupled with massive cellular metabolic adaptations, necessary to cope 
with different energy and metabolite requirements associated with switching from a 
resting to proliferative state. Furthermore, Th17 cells have to secure these metabolic 
adaptations when facing nutrient-limiting environments, such as at the sites of inflam-
mation. Accumulating data indicates that this metabolic reprogramming is significantly 
linked to the differentiation of T helper cells and, particularly, that the metabolic changes 
of Th17 cells and anti-inflammatory Forkhead box P3+ regulatory T cells are tightly and 
reciprocally regulated. Thus, a better understanding of these processes could offer 
potential new targets for therapeutic interventions for autoimmune diseases. In this 
mini-review, we will highlight some of the recent advances and discoveries in the field, 
with a particular focus on metabolic demands of Th17 cells and their implications for 
autoimmunity.
Keywords: glycolysis, oxidative phosphorylation, immunometabolism, interleukin-17-producing T helper cells, 
regulatory T cells, autoimmune diseases
inTRODUCTiOn
T cells respond to alterations in the host environment via multiple steps of activation, proliferation, 
and finally differentiation into specialized subsets, which are exquisitely programmed to deal with 
the challenge at hand; whether it is the presence of an intracellular or extracellular pathogen, or other 
alterations in tissue homeostasis, which may require either inflammatory or regulatory responses. 
These various responses are tightly regulated by the interplay of specialized CD4+ effector T helper 
(Th) cell subsets and antiinflammatory Forkhead box P3+ (FOXP3+) regulatory T cells (Tregs) (1).
One such type of a specialized T effector cell subset consists of interleukin (IL)-17-producing T 
helper (Th17) cells. In mice, Th17 cells could be differentiated from stimulated naive CD4+ T cells 
in the presence of the pleiotropic cytokine transforming growth factor (TGF)-β1 in combination 
with IL-6. Th17 cells are specialized to respond against certain bacterial and fungal pathogens in 
the tissue sites in which they are located, namely the mucosal linings of the gut and airway epithelia 
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(2). However, Th17 cells are also known for their pathogenic 
potential against the host, due to their association with several 
autoimmune diseases such as multiple sclerosis (MS), psoria-
sis, and rheumatoid arthritis (RA) (1–4). More recent studies 
have demonstrated that Th17  cells can be heterogeneous in 
phenotype and function and can even show antiinflammatory 
properties. This pro-inflammatory versus antiinflammatory/
homeostatic phenotype of Th17 cells seems to be determined 
by a set of specific signaling modules, where pathogenicity 
is critically influenced by a high level of expression of IL-23 
receptor, granulocyte-macrophage colony-stimulating factor, 
and Th1-like transcripts [e.g., interferon-γ, T-box transcription 
factor 21 (TBX21/Tbet)] and by the absence of the antiinflam-
matory cytokine IL-10 (5). The induction of these different 
Th17 phenotypes can be mimicked in vitro by varying the com-
bination of stimulatory triggers and cytokines. For example, the 
stimulation of naive T cells with a combination of IL-1β, IL-6, 
and IL-23 in the absence of TGF-β1 induces the differentiation 
of Th17 cells that exhibit a highly pro-inflammatory and patho-
genic phenotype, compared to “classically” TGF-β1 + IL-6 dif-
ferentiated Th17  cells (6–8). Together, these studies illustrate 
that the pro-inflammatory potential of Th17 cells is extremely 
sensitive to the presence and combinations of stimulatory cues 
within the local microenvironment.
Of course in  vivo, the tissue site in which Th17  cells are 
generated does not only consist of cytokines but is also packed 
with a variety of small molecules, including metabolites. This 
“metabolomic” milieu is dynamically changing in both its com-
position and concentration, which may have various effects on 
Th17 cells, particularly through their cellular metabolism (9–12). 
This is highlighted by many recent studies showing even further 
variation in Th17 phenotype can been fashioned in vitro by the 
addition of e.g., fatty acids (13, 14), phospholipids (15), choles-
terol intermediates (16), oxysterols (17, 18), and even electrolytes 
such as sodium or potassium (19, 20). In this mini-review, we will 
highlight some recent advances in understanding the metabolic 
adaptations and mechanisms employed by T  cells when they 
undergo activation and differentiate into specialized subsets, 
focusing on Th17 cells.
MeTABOLiC ADAPTATiOnS OF Th CeLLS
The overall aim of cellular metabolism, independently of the 
cell type, is to generate energy [adenosine triphosphate (ATP)] 
and metabolites, which are essential for cells to perform various 
functions, sustain life and growth. Glucose is the major cellular 
fuel source, and it is broken down into ATP by two separate, but 
connected pathways: glycolysis and oxidative phosphorylation 
(OXPHOS). In glycolysis, glucose is broken via 10 enzymatic steps 
down to pyruvate, yielding two ATP molecules; a process that 
does not require oxygen. Most cells go on to oxidize pyruvate in 
the tricarboxylic acid cycle, subsequently fueling mitochondrial 
OXPHOS, which, in an oxygen-dependent process, yields more 
than 30 ATP. Alternatively, pyruvate can be converted to lactate, 
which ultimately feeds back into glycolysis. While glycolysis 
produces far less ATP, it has several advantages in that it is fast 
and generates metabolites, so under oxygen-poor conditions, it 
can suffice to provide energy and necessary biomolecules for the 
cell (11, 12, 21).
A metabolic phenomena first observed in cancerous cells by 
Otto Warburg in 1924 is when proliferating cells preferentially 
utilize glycolytic metabolism even when oxygen is abundant 
(22). This aerobic glycolysis, often called “Warburg” metabolism, 
while bioenergetically less efficient, results in an additional 
benefit from increased flux into new molecules (nucleotides, 
amino acids, and fatty acids), as well as pathways involved in 
generation of redox-protective metabolites. It is now apparent 
that the activation of T cells induces this same metabolic switch 
to aerobic glycolysis (Figure 1). In fact, this was first observed 
more than 50 years ago that the activation of T cells, such as with 
mitogens like concanavalin A, results in immense changes in 
glycolytic cellular metabolism (23–27). More recently, Frauwirth 
et al. demonstrated the importance of costimulation in initiating 
these metabolic adaptations (28). Costimulation of CD3 and 
CD28 induced increased expression of the glucose transporter 
1 (Glut1), subsequently leading to augmented glucose uptake 
and flux through glycolysis. The same has been reported for the 
expression of amino acid transporters and amino acid uptake (29, 
30). Functionally, this provides the activated T cell with ATP, but 
more importantly, the accumulation of nutrients and biomass 
permits the activated T  cell to expand and rapidly proliferate. 
Adopting an aerobic glycolytic metabolism is now appreciated 
to be a feature of all Th cell populations (9–11, 21). Furthermore, 
this switch to aerobic glycolysis is not only limited to proliferat-
ing immune cells, as the activation of myeloid cells like dendritic 
cells (31) and macrophages (32) with toll-like receptor agonists 
also induces these same metabolic adaptations, indicating that 
this mechanism may infer a general requirement for cells of the 
immune system.
Th17 CeLLS veRSUS TReG: A CHOiCe  
in CeLLULAR MeTABOLiSM
For differentiation into special T effector cell subsets, cellular 
metabolism remains a process that is distinct and necessary for 
the acquisition of downstream specialized functions. This is none 
the more apparent when comparing the metabolic configurations 
of Th17  cells and Tregs. As a consequence of costimulation in 
combination with TGF-β and IL-6, the transcription factor RAR-
related orphan receptor gamma t (RORγt) is activated leading 
to the generation of Th17 cells. Conversely, while maintaining a 
requirement for TGF-β in the absence of other cytokines, with 
the exception of IL-2, induced Tregs (iTregs) are generated via 
the activation of the transcription factor FOXP3. Metabolically, 
these two subsets are incredibly distinct (13, 33, 34). In vitro 
stimulation of naïve T  cells with Th17-stimulating conditions 
induces robust glucose uptake and a shift to aerobic glycolysis. 
By contrast, Tregs instead increase their lipid uptake and utilize 
energy-efficient pathways such as fatty acid oxidation (FAO) and 
mitochondrial OXPHOS (Figure 1) (10–12, 21).
The key factors essential for the regulation of Treg and Th17 cell 
metabolic reprogramming have now been identified as a network 
of metabolic kinases that function as nutrient/energy sensors and 
metabolic transcription factors, in line with their regulation of 
FiGURe 1 | interleukin-17-producing T helper (Th17) cells and regulatory T cells (Tregs) have distinct metabolic requirements. The presentation of 
antigen and costimulation by dendritic cells induce the reprogramming of T cells into an aerobic glycolytic “Warburg” metabolism, characterized by the increased 
expression of glucose transporter 1 (Glut1) and augmented glucose uptake. Generally, in the presence of transforming growth factor (TGF)-β with the combination of 
other cytokines such as interleukin (IL)-6, activated T cells are polarized into specialized Th17 cells, which have an even further enhanced glycolytic metabolism and 
flux into intermediate pathways, required for the generation of amino acids, nucleotides, and fatty acids essential for Th17 effector function. Conversely, the induction 
of Tregs from activated T cells by TGF-β and the combination of other cytokines, such as IL-2, results in an increased uptake of fatty acids (FA) and an elevated lipid 
and mitochondrial oxidative metabolism. Within each subset, there exists further heterogeneity, depending on the presence of further local stimulatory cues, such as 
other cytokines and small metabolites, thus generating pathogenic or non-pathogenic Th17 cells and various polarized regulatory Treg cells; all of which exhibit 
further metabolic complexity. Th17 cells are dependent on aerobic glycolytic metabolism, as inhibiting glycolysis with 2-deoxyglucose (2-DG) or dichloroacetate 
(DCA) prevents Th17 cell generation even in the presence of Th17 cell-promoting conditions. Likewise, the addition of exogenous fatty acids or soraphen A (SorA), 
which enhances lipid oxidative metabolism, similarly inhibits Th17 cell generation. These metabolic interventions have the opposite effect on the generation of Tregs, 
which are conversely enhanced by treatments that augment lipid oxidative metabolism and blunted by inhibitors of lipid transport such as etomoxir. Cholesterol 
derivatives are essential for Th17 cell differentiation and blockade of cholesterol biosynthesis, for example, with ketoconazole, inhibits the generation of Th17 cells 
but has no effect on Tregs.
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nutrient transporter expression (9–12, 21, 35). Major regulatory 
checkpoints are mechanistic/mammalian target of rapamycin 
(mTOR), the kinase complex that is a promoter of aerobic glyco-
lysis and anabolic metabolism after stimulation of T cells and the 
AMP-activated protein kinase (AMPK) complex that promotes 
FAO and catabolic metabolism [reviewed in Ref. (9–12, 21, 35)]. 
Particularly for Th17  cells, the metabolic transcription factor, 
hypoxia-inducible factor 1 (HIF-1α), seems to play a special role 
(36). Under Th17-promoting conditions, HIF-1α expression 
is rapidly increased in an mTOR-dependent manner, and its 
deletion prevents the generation of Th17 cells both in vitro and 
in Th17-promoting disease models in vivo (34, 37). As HIF-1α 
is a transcription factor regulating the expression of metabolic 
enzymes (36), Shi et al. hypothesized its importance in regulating 
the cellular metabolic reprogramming of Th17 cells (34). Deletion 
of HIF-1α under Th17-promoting conditions results in a blunted 
upregulation of Glut1 and the reduced expression of crucial 
glycolytic enzymes such as hexokinase 2, phosphofructokinase 
1, and lactate dehydrogenase. Together, these data indicate 
that indeed HIF-1α is an essential facilitator of the acquisition 
of Th17 glycolytic metabolism (34). In line with this, a recent 
study identified another important regulatory checkpoint for 
Th17 cell or Treg-specific metabolic pathway decisions. Gerriets 
et al. identified pyruvate dehydrogenase (PDH) and the pyruvate 
metabolism as a key decisive point between T cell glycolytic and 
oxidative metabolism. The conversion of cytosolic pyruvate into 
mitochondrial acetyl-CoA is catalyzed by PDH for oxidative 
metabolism and is inhibited by PDH kinase (PDHK). PDHK is 
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Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 311
regulated by hypoxia and HIF-1α and promotes the generation 
of lactate by suppressing pyruvate oxidation (38). By a detailed 
metabolic analysis, they identified with PDHK1 an isoform that 
is predominantly expressed in Th17 cells but not in Th1 cells or 
Tregs. The inhibition of PDHK1 by dichloroacetate (DCA) was 
able to suppress glycolysis and selectively affected the generation 
and survival of Th17 cells in part through the generation of reac-
tive oxygen species (ROS) (38).
By contrast, both in vitro generated iTregs and ex vivo iso-
lated thymic-derived Tregs exhibit increased phosphorylation 
of AMPK (13), a broad sensor of decreased cellular nutrients 
and energy (39). Subsequently, treatment in  vivo with an 
AMPK agonist, metformin, resulted in an increased generation 
of Tregs (13). However, conversely, AMPK-knockout CD4+ 
T cells did not demonstrate deficient Treg generation (40). An 
explanation for these discrepant results may be because AMPK 
has a much broader role in T cell metabolic adaptations, not 
only within the Treg subset. Recently, Blagih et al. showed that 
T cells deficient in AMPK are unable to adapt in vitro changes 
in the availability of nutrients such as glucose and glutamine. 
Subsequently, this translated to an impaired ability of both 
Th1 and Th17 generation in  vivo (41), pointing toward mul-
tiple layers of cellular metabolic sensing and adaptation in the 
acquisition of T effector function, particularly for Th17 cells. 
In line with this, another metabolic checkpoint for fate deci-
sions between Tregs and Th17 cells was recently described (33). 
De novo fatty acid synthesis (FAS), which is inhibited by AMPK 
(42), was shown to be essential for the generation of Th17 cells 
in contrast to Tregs (33). Accordingly, the inhibition or dele-
tion of acetyl-CoA carboxylase 1 (ACC1), a key enzyme for 
de novo FAS, resulted in an impaired Th17 differentiation, 
whereas Tregs were induced (21, 33, 43).
These findings highlight how the generation of Tregs and 
Th17  cells is tightly linked to their metabolic state, offering 
potential new targets for the regulation of these two recipro-
cally regulated T  cell subsets (Figure  1). Indeed, it was shown 
already in addition to the targeting of AMPK with metformin 
that the inhibition of mTOR by rapamycin could block Th17 cell 
generation while favoring Tregs (11). Moreover, the inhibition of 
lipid oxidation with drugs such as etomoxir, which inhibits the 
activity of carnitine palmitoyltransferase I, resulting in a reduc-
tion of the fatty acid import into the mitochondria (44), impairs 
the differentiation of iTregs but has no effect on the generation 
of Th17 cells (13, 44). Conversely, inhibiting glucose metabolism 
with 2-deoxyglucose impairs Th17  cell differentiation while 
reciprocally promoting iTreg induction (34). Similarly, the addi-
tion of exogenous fatty acids (13) or the inhibition of de novo 
FAS with small-molecule metabolic modulators like soraphen 
A (SorA) (33) impairs Th17  cell differentiation and promotes 
Tregs, even in the presence of pro-Th17-inducing conditions. 
This does not mean, however, that Th17 cells do not require lipids 
for their metabolic remodeling. It has been recently shown that 
oxysterols, such as 27-dihydroxycholesterol (18), metabolites in 
the cholesterol biosynthetic pathway (16), and desmosterol (17) 
bind to, and agonize RORγt activity, subsequently promoting the 
differentiation of Th17 cells. Thus, inhibiting cholesterol synthe-
sis, for example with ketoconazole, impairs Th17 differentiation 
and IL-17 production, but has no effect on Treg differentiation 
(17). Moreover, PDHK1 blockade by DCA was able to selectively 
impair Th17 cell function and ameliorated experimental autoim-
mune encephalomyelitis (EAE) without having significant effects 
on Tregs or Th1 cells (38).
Th17 MeTABOLiSM: A POTenTiAL 
THeRAPeUTiC TARGeT FOR THe 
TReATMenT OF AUTOiMMUne 
DiSeASeS?
Under homeostatic conditions, Th17  cells are easily able to 
undergo the critical metabolic changes required for their 
specialized function described above, as nutrients are plentiful. 
However, under altered conditions (e.g., infection, disease, diet), 
metabolic restrictions may occur, which could have significant 
bearings on Th17 cell function. These recent discoveries discussed 
before highlight the intimate connectivity between immunity and 
cellular metabolism leading to the following questions: (a) Do 
disturbances in T cell metabolism contribute to the development 
of human autoimmune diseases? (b) Can Th17 metabolism be 
therapeutically targeted, thereby manipulating the immune 
system to become less inflammatory, and thus providing protec-
tion or treatment for autoimmune diseases with strong Th17 
components such as RA and MS?
Besides in animal models of disease, it has additionally been 
demonstrated that several autoimmune diseases go in line with 
metabolic alterations and that also T cells of patients have dys-
regulated metabolic profiles, indicating that indeed an altered 
T cell metabolism is associated with disease. This was for instance 
already shown for RA, systemic lupus erythematosus, and MS 
(11, 12, 45–47). Albeit for most of the diseases premature and 
incompletely understood, the notion of altered metabolic profiles 
in human autoimmunity points towards intriguing new avenues 
for therapeutic interventions. In fact, recent studies have gener-
ated promising experimental data indicating the feasibility of 
this hypothesis. Most of the current reports concentrated here 
on the reciprocal regulation in regards of cellular metabolism 
between Tregs and Th17 cells, since Th17 cells primarily depend 
on glycolysis and Tregs seem to utilize mainly FAO. As described 
above, the key targets here would be the inhibition of the mTOR/
HIF-1α pathway to prevent the development of the initiation of 
a “pro-inflammatory” metabolic signature or the activation of 
AMPK to influence cellular metabolism favoring the generation 
of antiinflammatory Tregs. In line with this, the interference of 
de novo FAS by inhibiting ACC1 with the inhibitor SorA was 
demonstrated to be effective at promoting the generation of 
Tregs, as well as inhibiting Th17 cells (33). However, the major 
problem, as for many other currently available immunotherapies, 
remains specificity. The above-mentioned metabolic reactions 
are all important in other T cell subsets and immune cells, and 
therefore, unspecific targeting of these pathways bears the risk 
of general immunosuppression and/or the interference with the 
generation of memory cells, which seem to have similar meta-
bolic demands as Tregs; not to mention effects on non-immune 
cells (9, 10, 12, 21). Moreover, it remains to be seen on how other 
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Th cell subsets react and in addition, importantly, on how these 
pathways interfere with pathogenic and regulatory/homeostatic 
subsets of Th17 cells (5). In this respect, it is of interest that it 
has already been demonstrated that an altered lipid biosynthesis 
and the fatty acid and cholesterol composition of the cell could 
impact Th17 cell pathogenicity by generating endogenous RORγt 
ligands (15–18).
It is also important to note that for many of the studies described 
in this review, there are only sparse data on the contribution of 
these same metabolic pathways to the differentiation of human 
Tregs and Th17 cells, and the contribution of these molecules to 
disease in vivo is not clear. Recent studies have, for instance, shown 
that in contrast to findings in murine Tregs, human Tregs in fact 
highly depend on glycolysis (46, 48). Similarly, murine Tregs 
have also been shown to be glycolytic in vivo (49). This obvious 
discrepancy of human to murine Tregs might be associated with 
the existence of different FOXP3 splice variants in humans, which 
could dictate their function in contrast to mice (50, 51). It was 
shown that glycolysis through the glycolytic enzyme enolase-1 
controls the induction of the FOXP3 splice variant containing 
exon 2 that is crucial for human Treg function (46). Therefore, 
defining metabolic targets depending only on in  vitro findings 
and experimental animal models must be carefully examined 
if they can be fully translated to the setting of human disease. 
Promising experimental strategies to cope with these problems 
might be the inclusion of different mouse models expressing 
different FOXP3 splice variants or the use of humanized mouse 
models, in combination with the analysis of patient samples as 
recently demonstrated by Yang et  al. for RA (52). This elegant 
study identified that patient samples exhibited a dysregulation 
in the pentose phosphate pathway (PPP), which was associated 
with a depletion in ROS. Insufficient oxidative signaling resulted 
in ataxia telangiectasia mutated kinase-dependent bypass of the 
G2/M cell cycle, consequently leading to hyperproliferation and a 
shift of RA patients into a highly pathogenic Th17/Th1 cell profile. 
Importantly, this dysregulation could be rescued by metabolic 
interventions that restored the ROS pool: supplementation 
with menadione (vitamin K3), disrupting synthesis of the ROS 
quencher glutathione, or by blocking glucose shunting into 
the PPP, which was even demonstrated in a humanized mouse 
model in vivo, transplanted with synovial tissue and T cells of RA 
patients (47, 52).
COnCLUSiOn
The research on immunometabolism and its relation to disease is an 
extremely fast growing and promising field, which may offer novel 
therapeutic avenues for immunomodulation in settings of various 
human diseases. Particularly in autoimmune diseases like RA or MS, 
metabolic disturbances influencing the Treg/Th17 axis may play a 
role, and we are just at the beginning to understand the tight linkage 
between metabolic pathways and immune cell function.
While this increased knowledge of the metabolic requirements 
and alterations of Th17 cells and Tregs in autoimmunity provides 
many specific targets for intervention, it may also offer indirect 
dietary approaches that beneficially influence dysregulated T cell 
metabolism by systemically changing nutrient or metabolite 
availability. This is not a new concept, as it is well known that 
nutrition and the general metabolic condition of individuals 
has a profound impact on the immune system. Malnutrition, 
particularly prominent in developing countries, is clearly associ-
ated with reduced immune function. By contrast, obesity, which 
is associated with a “Western” lifestyle and a nutritional pattern 
high in calories, fat, and salt, goes in hand with the onset of a 
low-grade systemic inflammation (12, 53, 54). While obesity is 
well known to predispose individuals to diabetes and cardiovas-
cular diseases, it additionally seems to represent a risk factor for 
inflammatory autoimmune diseases like MS (53, 55, 56). This 
may be driven largely by the strong effect of obesity on the Treg/
Th17 axis through various metabolites or adipokines like leptin 
and through pro-inflammatory cytokines like IL-6 (53, 57). An 
additional molecular mechanism contributing to this effect was 
recently described by Endo et al. Here, mice fed a high-fat diet 
had an elevated induction of Th17 differentiation, in a mechanism 
that was reliant on the expression of ACC1, which subsequently 
contributed to RORγt activation (43). Therefore, it is important 
to understand the direct and indirect influences of diet on the 
immune system and Treg/Th17 axis, or more broadly, the connec-
tion of systemic and cellular metabolism and its relation to human 
autoimmune disease (45). A variety of studies have indicated that 
particularly dietary interventions could have severe effects on 
autoimmunity by influencing metabolic parameters of immune 
cells. It is thus tempting to speculate that, for instance, dietary 
interventions like fasting mimicking diets, that were recently 
shown to be beneficial in EAE and MS patients by shifting the 
Treg/Th17 balance (58), or by lowering the sodium content in 
diets, that had a strong metabolic impact on macrophages (59, 
60), could serve as interesting alternatives or additions for drugs 
directly targeting cellular metabolism.
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